Carrington Hopes Dental Market Improves Earnings

Carrington Laboratories (CARN) has signed a 3 year representative agreement with Executive Sales Associates (ESA) to provide their SaliCept line of oral patches and rinses to dental practitioners.

SaliCept products provide relief of pain associated with various dental and oral conditions, including dry sockets following extractions, mucositis and stomatitis associated with chemotherapy, and other oral irritations.

Under the agreement ESA will be responsible for the marketing and sale of the SaliCept line through its 23 person sales network across the U.S.

Carrington hopes to increase its sales and bottom line after a disappointing third quarter earnings report released back on November 2. The company lossed $1.8 million compared to the $1.6 lossed the previous year.

Revenues increased by 18% over the previous year spearheaded by a 40% increase in its consumer products, while its services segment continued to disappoint. However, the company's total revenues actually decreased over the last nine months as compared to the previous year's nine month period.

With only a $43 million market cap, and a debt level equaling five times its cash position Carrington must improve its bottom line and sales numbers quick or the company's stock will be head down to penny land.

Shares of Carrington closed at $4 on Wednesday, with a 52-week price range of $2.76-$7.53

Carrington's all-time chart leaves much to be desired.

_